title: Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs.
abstract: OBJECTIVE
  To compare the clinical characteristics and the long-term outcome of a large series of patients with blepharospasm (BS) treated with the two most used brands of BoNT-A over the last 15 years.
  
  
  METHODS
  We have reviewed the clinical charts of 128 patients with BS who received botulinum neurotoxin (BoNT) in 1341 treatments (Botox in 1009, Dysport in 332) over the last 15 years.
  
  
  RESULTS
  Mean dose per session was 34U +/- 15 for Botox and 152U +/- 54 for Dysport. Mean latency of clinical effect was 4.5 +/- 4.6 days for Botox and 5.0 +/- 5.7 days for Dysport (P > 0.05). Mean duration of clinical improvement was higher for Dysport than Botox: 80.1 +/- 36.3 and 66.2 +/- 39.8 days, respectively (P < 0.01). In a six-point scale (0: no efficacy, 6: remission of BS), the mean efficacy of both treatments was 3.60 +/- 1.3; 3.51 +/- 1.4 (Botox) and 3.85 +/- 1.2 (Dysport), P < 0.01. The doses of Botox (beta = 0.40) and Dysport (beta = 0.16) were significantly increased over time. Side effects occurred in 325 out of 1341 treatments (24.2%): 21.8% of the patients who had received Botox, and in 31.6% of those who had received Dysport (P < 0.01).
  
  
  CONCLUSIONS
  Both brands are effective and safe in treating blepharospasm; efficacy is long lasting. The differences in outcome and side effects suggest that, albeit the active drug is the same, Botox and Dysport should be considered as two different drugs.
authors.affiliation: Istituto di Neurologia Università Cattolica del Sacro Cuore Largo Agostino Gemelli, 8 - 00168 Rome, Italy. annarita.bentivoglio@rm.unicatt.it
authors.forename: A R
authors.initials: AR
authors.lastname: Bentivoglio
authors.forename: A
authors.initials: A
authors.lastname: Fasano
authors.forename: T
authors.initials: T
authors.lastname: Ialongo
authors.forename: F
authors.initials: F
authors.lastname: Soleti
authors.forename: S
authors.initials: S
authors.lastname: Lo Fermo
authors.forename: A
authors.initials: A
authors.lastname: Albanese
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D001764:Blepharospasm / Q000188:drug therapy*; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D012189:Retrospective Studies; D013223:Statistics as Topic; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A